Microvascular dysfunction following primary percutaneous coronary intervention in the setting of ST-elevation myocardial infarction

Journal of Invasive Cardiology

Volumn 20, Issue 11, 2008, Pages 603-614

  Ramaraj, Radhakrishnan ^a   Movahed, Mohammad Reza ^a,b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE; ALLOPURINOL; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR; CARIPORIDE; CLOPIDOGREL; ENIPORIDE; GLUCAGON LIKE PEPTIDE; GLUCOSE; INSULIN; KAI 9803; MAGNESIUM; MCC 135; NICORANDIL; NORPHENAZONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEXELIZUMAB; POTASSIUM; PROTEIN KINASE C INHIBITOR; STREPTOKINASE; SUPEROXIDE DISMUTASE; TIROFIBAN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VERAPAMIL;

ACID BASE BALANCE; ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DEVICE; DRUG MEGADOSE; EMBOLISM PREVENTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HEART PERFUSION; HEART PROTECTION; HUMAN; INDUCED HYPOTHERMIA; INFLAMMATION; INVASIVE PROCEDURE; MICROANGIOPATHY; NON INVASIVE PROCEDURE; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; THROMBECTOMY; THROMBUS; THROMBUS ASPIRATION; UNSPECIFIED SIDE EFFECT; BLOOD FLOW VELOCITY; ELECTROCARDIOGRAPHY; MICROCIRCULATION; PATHOPHYSIOLOGY; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD FLOW VELOCITY; ELECTROCARDIOGRAPHY; HUMANS; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RISK FACTORS;

EID: 62449239613     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Boucek RJ, Murphy WP Jr. Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol 1960;6:525-533.
2. Henriques J P, Zijlstra F, Ottervanger J P, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002;23:1112-1127.
3. Kotani J, Mintz GS, Pregowski J, et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol 2003;92:728-732.
4. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
5. Svilaas T, van der Horst IC, Zijlstra F. Thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS) - Study design. Am Heart J 2006;151:597:e591-e597.
6. Gick M, Jander N, Bestehorn H P, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005;112:1462-1469.
7. Stone G W, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: A randomized controlled trial. JAMA 2005;293:1063-1072.
8. Sakuma T, Leong-Poi H, Fisher NG, et al. Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: The role of microthromboemboli. J Am Soc Echocardiogr 2003;16:15-21.
9. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38:291-300.
10. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
11. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004;109:1121-1126.
12. Ragosta M, Camarano G, Kaul S, et al. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction. New insights using myocardial contrast echocardiography. Circulation 1994;89:2562-2569.
13. Gregorini L, Marco J, Kozakova M, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999;99:482-490.
14. Hirsh PD, Hillis LD, Campbell WB, et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981;304:685-691.
15. Prasad A, Gersh BJ. Management of microvascular dysfunction and reperfusion injury. Heart 2005;91:1530-1532.
16. Gregorini L, Marco J, Palombo C, et al. Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. J Am Coll Cardiol 1998;31:992-1001.
17. el-Tamimi H, Davies GJ, Sritara P, et al. Inappropriate constriction of small coronary vessels as a possible cause of a positive exercise test early after successful coronary angioplasty. Circulation 1991;84:2307-2312.
18. Spyrou N, Khan MA, Rosen SD, et al. Persistent but reversible coronary microvascular dysfunction after bypass grafting. Am J Physiol Heart Circ Physiol 2000;279:H2634-H2640.
19. Frink RJ, Rooney PA, Jr, Trowbridge JO, Rose J P. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988;59:196-200.
20. Beranek J T. C-reactive protein and complement in myocardial infarction and postinfarction heart failure. Eur Heart J 1997;18:1834-1836.
21. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-1149.
22. Krug A, Du Mesnil de R, Korb G. Blood supply of the myocardium after temporary coronary occlusion. Circ Res 1966;19:57-62.
23. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006;3:499-506.
24. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol 1984;16:497-518.
25. Piek JJ. Beyond epicardial reperfusion. N Engl J Med 2007;356:1880-1882.
26. Galiuto L. Optimal therapeutic strategies in the setting of post-infarct no reflow: The need for a pathogenetic classification. Heart 2004;90:123-125.
27. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the "no reflow" phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-228.
28. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-772.
29. Spaan JA, Piek JJ, Hoffman JI, Siebes M. Physiological basis of clinically used coronary hemodynamic indices. Circulation 2006;113:446-455.
30. van't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet 1997;350:615-619.
31. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.
32. Kaufmann PA, Camici PG. Myocardial blood flow measurement by PET: Technical aspects and clinical applications. J Nucl Med 2005;46:75-88.
33. Agati L, Tonti G, Galiuto L, et al. Quantification methods in contrast echocardiog-raphy. Eur J Echocardiogr 2005;6(Suppl 2):S14-S20.
34. Jerosch-Herold M, Wilke N, Stillman AE. Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution. Med Phys 1998;25:73-84.
35. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989;320:618-627.
36. Gibson CM, Cannon C P, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
37. van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302-2306.
38. Barbato E, Aarnoudse W, Aengevaeren WR, et al. Validation of coronary flow reserve measurements by thermodilution in clinical practice. Eur Heart J 2004;25:219-223.
39. de Lemos JA, Warner JJ. New tools for assessing microvascular obstruction in patients with ST-elevation myocardial infarction. Heart 2004;90:119-120.
40. Iwakura K, Ito H, Kawano S, et al. Assessing myocardial perfusion with the transthoracic Doppler technique in patients with reperfused anterior myocardial infarction: Comparison with angiographic, enzymatic and electrocardiographic indices. Eur Heart J 2004;25:1526-1533.
41. Ng MK, Yeung AC, Fearon W F. Invasive assessment of the coronary microcircula-tion: Superior reproducibility and less hemodynamic dependence of index of micro-circulatory resistance compared with coronary flow reserve. Circulation 2006;113:2054-2061.
42. Pijls NH, Bech GJ, el Gamal MI, et al. Quantification of recruitable coronary collateral blood flow in conscious humans and its potential to predict future ischemic events. J Am Coll Cardiol 1995;25:1522-1528.
43. Werner GS, Ferrari M, Richartz BM, et al. Microvascular dysfunction in chronic total coronary occlusions. Circulation 2001;104:1129-1134.
44. De Bruyne B, Pijls NH, Smith L, et al. Coronary thermodilution to assess flow reserve: Experimental validation. Circulation 2001;104:2003-2006.
45. Fearon W F, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the coronary microcirculation. Circulation 2003;107:3129-1232.
46. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006;70:181-190.
47. Zhao X, He G, Chen YR, et al. Endothelium-derived nitric oxide regulates postis-chemic myocardial oxygenation and oxygen consumption by modulation of mito-chondrial electron transport. Circulation 2005;111:2966-2972.
48. Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation 1999;100:1609-1615.
49. Alexander JH, Reynolds HR, Stebbins AL, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: The TRIUMPH randomized controlled trial. JAMA 2007;297:1657-1666.
50. Ono H, Osanai T, Ishizaka H, et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004;148:E15.
51. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005;112:1284-1288.
52. Klein HH, Pich S, Lindert S, et al. Treatment of reperfusion injury with intracoronary calcium channel antagonists and reduced coronary free calcium concentration in regionally ischemic, reperfused porcine hearts. J Am Coll Cardiol 1989;13:1395-1401.
53. Carry MM, Mrak RE, Murphy ML, et al. Reperfusion injury in ischemic myocardium: Protective effects of ruthenium red and of nitroprusside. Am J Cardiovasc Pathol 1989;2:335-344.
54. Gumina RJ, Buerger E, Eickmeier C, et al. Inhibition of the Na(+)/H(+) exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than is-chemic preconditioning in dogs. Circulation 1999;100:2519-2526.
55. Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet 2000;355:1751-1756.
56. Zeymer U, Suryapranata H, Monassier J P, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001;38:1644-1650.
57. Lemasters JJ, Bond JM, Chacon E, et al. The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS 1996;76:99-114.
58. Bond JM, Herman B, Lemasters JJ. Protection by acidotic pH against anoxia/reoxy-genation injury to rat neonatal cardiac myocytes. Biochem Biophys Res Commun 1991;179:798-803.
59. Kim JS, Jin Y, Lemasters JJ. Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2006;290:H2024-H2034.
60. George I, Yi GH, Schulman AR, et al. A polymerized bovine hemoglobin oxygen carrier preserves regional myocardial function and reduces infarct size after acute myocardial ischemia. Am J Physiol Heart Circ Physiol 2006;291:H1126-H1137.
61. Buerke M, Rupprecht HJ, vom Dahl J, et al. Sodium-hydrogen exchange inhibition: Novel strategy to prevent myocardial injury following ischemia and reperfusion. Am J Cardiol 1999;83:19G-22G.
62. Erhardt LR. GUARD During Ischemia Against Necrosis (GUARDIAN) trial in acute coronary syndromes. Am J Cardiol 1999;83:23G-25G.
63. Portman MA, Panos AL, Xiao Y, et al. HOE-642 (cariporide) alters pH(i) and dias-tolic function after ischemia during reperfusion in pig hearts in situ. Am J Physiol Heart Circ Physiol 2001;280:H830-H834.
64. Avkiran M, Marber MS. Na(+)/H(+) exchange inhibitors for cardioprotective therapy: Progress, problems and prospects. J Am Coll Cardiol 2002;39:747-753.
65. Litt MR, Jeremy RW, Weisman H F, et al. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophilmediated reperfusion injury. Circulation 1989;80:1816-1827.
66. Hayward R, Campbell B, Shin YK, et al. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999;41:65-76.
67. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991;88:1237-1243.
68. Zhao ZQ, Lefer DJ, Sato H, et al. Monoclonal antibody to ICAM-1 preserves postis-chemic blood flow and reduces infarct size after ischemia-reperfusion in rabbit. J Leukoc Biol 1997;62:292-300.
69. Vakeva A P, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after my-ocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-2267.
70. Mahaffey K W, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-1183.
71. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-1190.
72. Armstrong P W, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial. JAMA 2007;297:43-51.
73. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 1989;80:1388-1399.
74. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adeno-sine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-2159.
75. Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: The ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 2003;146:146-1452.
76. Forman MB, Stone G W, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24:116-147.
77. Ross AM, Gibbons RJ, Stone G W, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780.
78. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: The AMIS-TAD-2 trial. Eur Heart J 2006;27:2400-2405.
79. Olafsson B, Forman MB, Puett DW, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the no-reflow phenomenon. Circulation 1987;76:1135-1145.
80. Goto M, Miura T, Iliodoromitis EK, et al. Adenosine infusion during early reperfu-sion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 1991;25:943-949.
81. Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 1996;97:493-500.
82. Matsushita K, Morrell CN, Lowenstein CJ. A novel class of fusion polypeptides inhibits exocytosis. Mol Pharmacol 2005;67:113-1144.
83. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001;89:1191-1198.
84. Apstein CS, Opie LH. A challenge to the metabolic approach to myocardial is-chaemia. Eur Heart J 2005;26:956-959.
85. Christensen CW, Rieder MA, Silverstein EL, Gencheff NE. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reper-fusion in a canine model. Circulation 1995;92:2617-2621.
86. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-446.
87. Diaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007;298:2399-2405.
88. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553-1558.
89. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-685.
90. Santoro GM, Antoniucci D, Bolognese L, et al. A randomized study of intravenous magnesium in acute myocardial infarction treated with direct coronary angioplasty. Am Heart J 2000;140:891-897.
91. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: A randomised controlled trial. Lancet 2002;360:1189-1196.
92. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-556.
93. Chien GL, Wolff RA, Davis RF, van Winkle DM. "Normothermic range" temperature affects myocardial infarct size. Cardiovasc Res 1994;28:1014-1017.
94. Dae MW, Gao DW, Sessler DI, et al. Effect of endovascular cooling on myocardial temperature, infarct size, and cardiac output in human-sized pigs. Am J Physiol Heart Circ Physiol 2002;282:H1584-H1591.
95. Dixon SR, Whitbourn RJ, Dae M W, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002;40:1928-1934.
96. Ly HQ, Denault A, Dupuis J, et al. A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study). Am Heart J 2005;150:933.
97. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
98. Heusch G. Postconditioning: Old wine in a new bottle? J Am Coll Cardiol 2004;44:1111-1112.
99. Zhao ZQ, Vinten-Johansen J. Postconditioning: Reduction of reperfusion-induced injury. Cardiovasc Res 2006;70:200-211.
100. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: Staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 2007;115:1895-1903.
101. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460.
102. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: Its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003;35:339-341.
103. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: Taking a RISK for cardioprotection. Heart Fail Rev 2007;12:217-234.
104. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: A common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005;15:69-75.
105. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: A prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004;109:1704-1706.
106. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
107. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003;108:1316-1323.
108. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-741.
109. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-921.
110. Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: A randomized controlled trial. JAMA 2004;291:947-954.
111. Armstrong PW, Mahaffey KW, Chang WC, et al. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. Am Heart J 2006;151:787-790.
112. Gibson CM, Singh K P, Murphy SA, et al. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). Am J Cardiol 2004;94:492-494.
113. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycopro-tein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
114. Bejarano J. Mechanical protection of cardiac microcirculation during percutaneous coronary intervention of saphenous vein grafts. Int J Cardiol 2005;99:365-372.
115. Limbruno U, Micheli A, De Carlo M, et al. Mechanical prevention of distal embolization during primary angioplasty: Safety, feasibility, and impact on myocardial reperfusion. Circulation 2003;108:171-176.
116. Asanuma T, Tanabe K, Ochiai K, et al. Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocar-dial infarction: Myocardial contrast echocardiographic study. Circulation 1997;96:448-453.
117. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-755.
118. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-2020.
119. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
120. Beran G, Lang I, Schreiber W, et al. Intracoronary thrombectomy with the X-sizer catheter system improves epicardial flow and accelerates ST-segment resolution in patients with acute coronary syndrome: A prospective, randomized, controlled study. Circulation 2002;105:2355-2360.
121. Napodano M, Pasquetto G, Sacca S, et al. Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003;42:1395-1402.
122. Lefevre T, Garcia E, Reimers B, et al. X-sizer for thrombectomy in acute myocardial infarction improves ST-segment resolution: Results of the X-sizer in AMI for negligible embolization and optimal ST resolution (X AMINE ST) trial. J Am Coll Cardiol 2005;46:246-252.
123. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358:557-567.
124. Burzotta F, Trani C, Romagnoli E, et al. Manual thrombus-aspiration improves my-ocardial reperfusion: The randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (RE-MEDIA) trial. J Am Coll Cardiol 2005;46:371-376.
125. Faxon D P, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-1204.
126. Guan W, Osanai T, Kamada T, et al. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol 2003;41:699-705.
127. Tsujita K, Shimomura H, Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ J 2006;70:832-837.
128. Flaherty JT, Pitt B, Gruber J W, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994;89:1982-1991.
129. Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation 2000;102:3032-3038.
130. Bar F W, Tzivoni D, Dirksen MT, et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: The randomized multicentre CASTEMI study. Eur Heart J 2006;27:2516-2523.
131. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
132. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Tw o randomised trials. Lancet 2007;370:1483-1493.
133. Hang CL, Wang C P, Yip HK, et al. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest 2005;128:2593-2598.
134. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-1278.
135. Lipsic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythro-poietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-141.
136. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965.
137. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: A pilot study. Catheter Cardiovasc Interv 2005;65:361-367.
138. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005;112:2143-2148.
139. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 2006;19:367-375.
140. Sezer M, Oflaz H, Goren T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med 2007;356:1823-1834.
141. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548-553.